Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials

Objectives. RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MM...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendas-Baum, Regina, Kosinski, Mark, Singh, Amitabh, Mebus, Charles A., Wilkinson, Bethany E., Wallenstein, Gene V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850117/
https://www.ncbi.nlm.nih.gov/pubmed/28460083
http://dx.doi.org/10.1093/rheumatology/kex087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850117/
https://www.ncbi.nlm.nih.gov/pubmed/28460083
http://dx.doi.org/10.1093/rheumatology/kex087

Ejemplares similares